Skip to content

    Recently Viewed

      Listening...

      lede-A Message from Chairman and CEO Alex Gorsky About Johnson & Johnson's Investigational COVID-19 Vaccine Candidate.jpg

      A message from Chairman and CEO Alex Gorsky about the Emergency Use Authorization of Johnson & Johnson’s Janssen COVID-19 vaccine

      The company leader shares the latest news about the U.S. Food and Drug Administration’s decision about the single-shot Janssen COVID-19 vaccine.

      Share Article
      share to

      Today the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization for Johnson & Johnson’s Janssen COVID-19 vaccine—marking the culmination of a year of extraordinary innovation and collaboration by the people of Johnson & Johnson.

      I know I speak on behalf of all of us when I say how proud and grateful we are for this opportunity to contribute our single-shot vaccine to the global effort to defeat COVID-19.

      Just as the FDA’s decision reflects the urgency of the situation, we are moving forward without delay to ensure we can make the maximum possible impact with our vaccine.

      After much hard work and preparation, Johnson & Johnson is ready to join the fight on the ground against COVID-19 and eager to help bring this pandemic to an end—not just in the United States, but throughout the world.

      As we continue to pursue regulatory authorization around the world, our company is on track to meet our manufacturing goals, committed to making our vaccine available on a not-for-profit basis for pandemic emergency use and confident in the strength of the data from our clinical trials. Tested at the height of the pandemic, our vaccine has shown its potential to significantly reduce the burden of severe disease with just one immunization.

      After much hard work and preparation, Johnson & Johnson is ready to join the fight on the ground against COVID-19 and eager to help bring this pandemic to an end—not just in the United States, but throughout the world.

      More from Johnson & Johnson

      Innovation
      Two cardiac electrophysiologists performing a cardiac ablation procedure to treat AFib

      What is cardiac ablation?

      For American Heart Month, learn how Johnson & Johnson is innovating to help treat the millions of people who are living with atrial fibrillation and other conditions that cause an irregular heartbeat.
      Latest news
       Biomedical scientist Robert Langer headshot

      Biomedical scientist Robert Langer receives the 2023 Dr. Paul Janssen Award for Biomedical Research

      Each year, Johnson & Johnson honors a scientist currently working in academia, industry or a scientific institute who has made a significant contribution toward the improvement of public health.
      Health & wellness
       Blue latex gloved hand pointing at a brain MRI scan to pinpoint brain circuits associated with depression symptoms

      Is this the end of one-size-fits-all treatments for depression?

      Johnson & Johnson is working to bring personalized psychiatry to the 7 in 10 people with depression whose treatments aren’t getting the job done.
      You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.